Format

Send to

Choose Destination
Mol Cancer. 2015 Jun 17;14:121. doi: 10.1186/s12943-015-0398-x.

Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo.

Author information

1
Vilhelm Magnus Laboratory for Neurosurgical Research, Department of Neurosurgery and Institute of Surgical Research, Oslo University Hospital, Oslo, Norway. mrinaj@medisin.uio.no.
2
Laboratory of Neural Development and Optical Recording (NDEVOR), Department of Physiology, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway. mrinaj@medisin.uio.no.
3
Norwegian Center for Stem Cell Research, Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway. mrinaj@medisin.uio.no.
4
Present Address: Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. mrinaj@medisin.uio.no.
5
Vilhelm Magnus Laboratory for Neurosurgical Research, Department of Neurosurgery and Institute of Surgical Research, Oslo University Hospital, Oslo, Norway. awaismu@rr.research.no.
6
Vilhelm Magnus Laboratory for Neurosurgical Research, Department of Neurosurgery and Institute of Surgical Research, Oslo University Hospital, Oslo, Norway. zanina_grieg@yahoo.no.
7
Norwegian Center for Stem Cell Research, Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway. zanina_grieg@yahoo.no.
8
Vilhelm Magnus Laboratory for Neurosurgical Research, Department of Neurosurgery and Institute of Surgical Research, Oslo University Hospital, Oslo, Norway. wayne.murrell@rr-research.no.
9
Vilhelm Magnus Laboratory for Neurosurgical Research, Department of Neurosurgery and Institute of Surgical Research, Oslo University Hospital, Oslo, Norway. sheryl_palmero@hotmail.com.
10
Vilhelm Magnus Laboratory for Neurosurgical Research, Department of Neurosurgery and Institute of Surgical Research, Oslo University Hospital, Oslo, Norway. Birthe.Mikkelsen@rr-research.no.
11
Laboratory of Neural Development and Optical Recording (NDEVOR), Department of Physiology, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway. Hege.Fjerdingstad@rr-research.no.
12
Norwegian Center for Stem Cell Research, Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway. Hege.Fjerdingstad@rr-research.no.
13
Vilhelm Magnus Laboratory for Neurosurgical Research, Department of Neurosurgery and Institute of Surgical Research, Oslo University Hospital, Oslo, Norway. cesandbe@medisin.uio.no.
14
Vilhelm Magnus Laboratory for Neurosurgical Research, Department of Neurosurgery and Institute of Surgical Research, Oslo University Hospital, Oslo, Norway. jinan_bahnan@hotmail.com.
15
Laboratory of Neural Development and Optical Recording (NDEVOR), Department of Physiology, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway. joel.glover@medisin.uio.no.
16
Oslo University Hospital, SFI-CAST Biomedical Innovation Center, Oslo, Norway. joel.glover@medisin.uio.no.
17
Norwegian Center for Stem Cell Research, Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway. joel.glover@medisin.uio.no.
18
Vilhelm Magnus Laboratory for Neurosurgical Research, Department of Neurosurgery and Institute of Surgical Research, Oslo University Hospital, Oslo, Norway. i.a.langmoen@medisin.uio.no.
19
Oslo University Hospital, SFI-CAST Biomedical Innovation Center, Oslo, Norway. i.a.langmoen@medisin.uio.no.
20
Norwegian Center for Stem Cell Research, Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway. i.a.langmoen@medisin.uio.no.
21
Vilhelm Magnus Laboratory for Neurosurgical Research, Department of Neurosurgery and Institute of Surgical Research, Oslo University Hospital, Oslo, Norway. biljana.stangeland@labmed.uio.no.
22
Oslo University Hospital, SFI-CAST Biomedical Innovation Center, Oslo, Norway. biljana.stangeland@labmed.uio.no.

Abstract

BACKGROUND:

Glioblastomas are invasive therapy resistant brain tumors with extremely poor prognosis. The Glioma initiating cell (GIC) population contributes to therapeutic resistance and tumor recurrence. Targeting GIC-associated gene candidates could significantly impact GBM tumorigenicity. Here, we investigate a protein kinase, PBK/TOPK as a candidate for regulating growth, survival and in vivo tumorigenicity of GICs.

METHODS:

PBK is highly upregulated in GICs and GBM tissues as shown by RNA and protein analyses. We knocked down PBK using shRNA vectors and inhibited the function of PBK protein with a pharmacological PBK inhibitor, HITOPK-032. We assessed viability, tumorsphere formation and apoptosis in three patient derived GIC cultures.

RESULTS:

Gene knockdown of PBK led to decreased viability and sphere formation and in one culture an increase in apoptosis. Treatment of cells with inhibitor HITOPK-032 (5 μM and 10 μM) almost completely abolished growth and elicited a large increase in apoptosis in all three cultures. HI-TOPK-032 treatment (5 mg/kg and 10 mg/kg bodyweight) in vivo resulted in diminished growth of experimentally induced subcutaneous GBM tumors in mice. We also carried out multi-culture assays of cell survival to investigate the relative effects on GICs compared with the normal neural stem cells (NSCs) and their differentiated counterparts. Normal NSCs seemed to withstand treatment slightly better than the GICs.

CONCLUSION:

Our study of identification and functional validation of PBK suggests that this candidate can be a promising molecular target for GBM treatment.

PMID:
26081429
PMCID:
PMC4470057
DOI:
10.1186/s12943-015-0398-x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center